Abdominal obesity drives the development of cardiometabolic risks through altered secretion of adipocyte-derived active substances called adipokines, including free fatty acids, adiponectin, interleukin-6, tumour necrosis factor-alpha, and plasminogen activator inhibitor-1, and through exacerbation of insulin resistance and associated cardiometabolic risk factors36. This evidence concerns the gene ADIPOQ and Abdominal obesity.